Optimal drugs for HIPEC in different tumors

Area of Science:

• Oncology
• Surgical Oncology
• Pharmacology

Background:

• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are established treatments for peritoneal surface malignancies.
• However, HIPEC procedures, particularly drug selection, lack standardization, necessitating optimization.

Purpose of the Study:

• To discuss the characteristics of an optimal HIPEC drug.
• To analyze drug choices for HIPEC in various peritoneal surface malignancies.
• To highlight the need for further research into drug efficacy and personalized treatment.

Main Methods:

• Review of current HIPEC practices and drug selection criteria.
• Analysis of drug characteristics relevant to HIPEC efficacy.
• Discussion of drug choices for specific peritoneal surface malignancies.

Main Results:

• Significant variations exist in current HIPEC drug selection protocols.
• No single drug is universally optimal; characteristics of an ideal HIPEC drug are outlined.
• Prospective randomized trials are needed to determine the most effective HIPEC drug for each malignancy type.

Conclusions:

• Standardization of HIPEC procedures, especially drug choice, is essential for improved patient outcomes.
• Future research should focus on prospective trials to identify optimal drugs for specific peritoneal malignancies.
• Personalized drug selection based on tumor sensitivity testing holds significant promise for future HIPEC treatments.